Cargando…

Postoperative Radiotherapy for Patients with Completely Resected Pathological Stage IIIA-N2 Non-small Cell Lung Cancer: A Preferential Benefit for Squamous Cell Carcinoma

BACKGROUND: The beneficial effect of postoperative radiotherapy (PORT) on completely resected pathological IIIA-N2 (pIIIA-N2) non-small cell lung cancer (NSCLC) has been a subject of interest with controversy. The aim of the study was to distinguish the clinical efficacy of PORT on lung adenocarcino...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Cuimeng, Liu, Guimei, Xu, Yongxiang, Xia, Guangrong, Zhang, Tongmei, Huang, Jiaqiang, Jiang, Hui, Ming Wang, Ji, Li, Baolan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877270/ https://www.ncbi.nlm.nih.gov/pubmed/33885242 http://dx.doi.org/10.2478/raon-2020-0070

Ejemplares similares

Beneficial effects of postoperative radiotherapy for IIIA‑N2 non‑small cell lung cancer after radical resection analysed using the propensity score‑matching method
por: Tian, Cuimeng, et al.
Publicado: (2023)

Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy
por: Hui, Zhouguang, et al.
Publicado: (2015)

Postoperative Radiotherapy in Completely Resected IIIA-N2 Non-small Cell Lung Cancer: Quit or Not?
por: Chen, Yu, et al.
Publicado: (2023)

Postoperative radiotherapy for pathological stage IIIA‐N2 non‐small cell lung cancer with positive surgical margins
por: Yuan, Meng, et al.
Publicado: (2020)

An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer
por: Berman, Abigail T, et al.
Publicado: (2013)

Radiotherapy for patients with completely resected pathologic IIIA(N2) non–small-cell lung cancer: a retrospective analysis
por: Zhu, Ying, et al.
Publicado: (2019)

Postoperative radiotherapy for patients with completely resected stage IIIA‐N2 non‐small cell lung cancer: opt‐in or opt‐out
por: Zhu, Lucheng, et al.
Publicado: (2022)

Log odds of positive lymph nodes is a robust predictor of survival and benefits from postoperative radiotherapy in stage IIIA‐N2 resected non‐small cell lung cancer
por: Jin, Xing, et al.
Publicado: (2022)

Early postoperative radiotherapy is associated with improved outcomes over late postoperative radiotherapy in the management of completely resected (R0) Stage IIIA-N2 non-small cell lung cancer
por: Wang, Huan-Huan, et al.
Publicado: (2017)

Topoisomerase I expression is associated with prognosis in postoperative non‐small cell lung cancer patients
por: Lu, Baohua, et al.
Publicado: (2016)

Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database
por: Wang, Xia, et al.
Publicado: (2021)

Differential MUC22 expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma
por: Lin, Shuye, et al.
Publicado: (2021)

Outcomes following oropharyngeal squamous cell carcinoma resection and bilateral neck dissection with or without contralateral postoperative radiotherapy of the pathologically node-negative neck
por: Jansen, Florian, et al.
Publicado: (2023)

Patient prognostic scores and association with survival improvement offered by postoperative radiotherapy for resected IIIA/N2 non‐small cell lung cancer: A population‐based study
por: Xu, Lei, et al.
Publicado: (2021)

Delineation of clinical target volume for postoperative radiotherapy in stage IIIA-pN2 non-small-cell lung cancer
por: Jing, Xuquan, et al.
Publicado: (2016)

Value of postoperative radiotherapy for stage IIIa-N2 non-small cell lung cancer: an analysis based on SEER database
por: Yang, Ran, et al.
Publicado: (2022)

The role of postoperative radiotherapy for completely resected pIIIA-N2 non-small cell lung cancer patients with different clinicopathological features: a systemic review and meta-analysis
por: Liu, Tingting, et al.
Publicado: (2019)

Real world practice of postoperative radiotherapy for patients with completely resected pIIIA-N2 non-small cell lung cancer: a national survey of radiation oncologists in China
por: Zhou, Shujie, et al.
Publicado: (2023)

Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer
por: Ding, Xiao, et al.
Publicado: (2012)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
por: Li, Xin, et al.
Publicado: (2022)

Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis
por: Xu, Ya-Ping, et al.
Publicado: (2015)

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial
por: Hui, Zhouguang, et al.
Publicado: (2021)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

The high-risk features and effect of postoperative radiotherapy on survival for patients with surgically treated stage IIIA-N2 non-small cell lung cancer
por: Zhu, Minxia, et al.
Publicado: (2023)

Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number
por: Wang, Siwei, et al.
Publicado: (2017)

Survival Analysis of 159 Patients With Advanced Non-Small-Cell Lung Cancer Resistant to First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
por: Hu, Aimin, et al.
Publicado: (2023)

Structure of sulfamidase provides insight into the molecular pathology of mucopolysaccharidosis IIIA
por: Sidhu, Navdeep S., et al.
Publicado: (2014)

The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy
por: Yang, Hui, et al.
Publicado: (2021)

Role of Postoperative Radiotherapy for Microscopic Margin Involvement in the Squamous Cell Carcinoma of Esophagus
por: Song, Sanghyuk, et al.
Publicado: (2013)

The impact of national holidays on postoperative radiotherapy of squamous cell carcinoma of the head and neck
por: Kim, Michael S., et al.
Publicado: (2023)

The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume
por: Feng, Wen, et al.
Publicado: (2015)

Efficacy of intensity-modulated radiotherapy for resected thoracic esophageal squamous cell carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2015)

Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection
por: Lowczak, Anna, et al.
Publicado: (2020)

Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment
por: Brascia, Debora, et al.
Publicado: (2020)

Propensity score-matching analysis of postoperative radiotherapy for stage IIIA-N2 non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database
por: Wei, Shenhai, et al.
Publicado: (2017)

The Dosimetric Comparisons of CRT, IMRT, ARC, CRT+IMRT, and CRT+ARC of Postoperative Radiotherapy in IIIA-N2 Stage Non-Small-Cell Lung Cancer Patients
por: Zhang, Yanqiu, et al.
Publicado: (2019)

A Rare Subtype of Non-small Cell Lung Cancer: Report of 159 Resected Pathological Stage I–IIIA Pulmonary Lymphoepithelioma-Like Carcinoma Cases
por: Jiang, Rong-Rong, et al.
Publicado: (2021)

A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
por: Liu, Yanxia, et al.
Publicado: (2022)

Dosimetric comparison of carbon ion and X-ray radiotherapy for Stage IIIA non–small cell lung cancer
por: Kubo, Nobuteru, et al.
Publicado: (2016)

Select octogenarians with stage IIIa non–small cell lung cancer can benefit from trimodality therapy
por: Tang, Andrew, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_91m59loe8rov3lh9bvd27hqmar